Leading the Nano-Bio Revolution in Diagnostics
Elevate your expectations in healthcare diagnostics with QMC Health Inc., the global leader in precise, high-sensitivity, rapid point-of-care technologies. Our revolutionary nano-biotechnologies are on the verge of reshaping the entire point-of-care healthcare landscape.
Unleashing the power of our patent-pending quantum dot nanoconjugates, we've achieved unparalleled test sensitivity, pushing detection limits down to an incredible 1.25 picogram per milliliter. These results not only rival but surpass those of costly and time-consuming molecular tests.
What sets us apart? Scalability. Our technology is designed to disrupt the status quo, seamlessly integrating with the existing lateral flow assay high-volume manufacturing infrastructure. This strategic approach allows us to rapidly expand, reaching underserved populations globally. Join us in revolutionizing healthcare accessibility and accuracy!
Collaboration
Step into the future with QMC Health, a visionary nanotechnology company born in 2018, pioneering groundbreaking rapid testing that elevates performance through cutting-edge nanotech biomarker conjugates.
Our technology is a game-changer, propelling a diverse range of tests – from Sepsis and COVID to Long-COVID, UTI, and Troponin – into new realms of qualitative, semiquantitative, and quantitative resolutions.
But that's not all – our Quantum Optics team has crafted advanced reader technology that, when paired with our proprietary reader software, enables semi-quantitative test result data collection and unlocks the full potential of quantum fluorescent signal enhancement properties. This dynamic duo significantly broadens the spectrum of crucial data, empowering therapeutic management and enhancing pandemic response.
Join us in reshaping the landscape of diagnostics and response capabilities!
email us at info@qmc-health.com or
Rapid Diagnostics, Diagnostic test kits, quantum optics,
Biomarkers, Pandemic, Pandemic Response, Disease X.
In The News
Thrilled to announce a major milestone for QMC Health Inc.!
Kudos to our exceptional team for reaching new heights in rapid, low-cost lateral flow diagnostics. Leveraging our cutting-edge nano-bioconjugation technologies, we've achieved a groundbreaking 1.0 picogram/ML detection using SARS Covid antibodies. This scalable technology is set to revolutionize the industry, capitalizing on our existing, global, high-volume lateral flow assay infrastructure.
https://www.linkedin.com/company/89758299/admin/feed/posts/
"London researchers discover novel method to diagnose Long COVID"
"Elevated vascular transformation blood biomarkers in Long-COVID indicate angiogenesis as a key pathophysiological mechanism," Molecular Medicine 28, 122 (2022)
© 2023 by QMC health, Inc. Proudly created with Wix.com